Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05879250 · ClinicalTrials.gov registry record · Phase 2
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
A Phase 2 study of Glioblastoma, IDH-wildtype and MGMT-Unmethylated Glioblastoma, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 2
- Study locations
NCT05879250: Recruiting Phase 2 study of Glioblastoma, IDH-wildtype and MGMT-Unmethylated Glioblastoma, sponsored by Northwestern University.
NCT05879250 is a Phase 2 study of Glioblastoma, IDH-wildtype and MGMT-Unmethylated Glioblastoma that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 39 participants, below the 275-participant average among 15 other Glioblastoma, IDH-wildtype trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05879250, a Phase 2 study of Glioblastoma, IDH-wildtype and MGMT-Unmethylated Glioblastoma, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial tests how well the combination of WP1066 and radiation therapy works in treating newly diagnosed glioblastoma. Glioblastoma is difficult to treat effectively because the cells within the tumor vary widely and are controlled by factors within and around the tumor, requiring multiple approaches to treat the tumor. The study drug WP1066 targets a specific pathway, known as STAT3, which is responsible for promoting tumor growth and causing the body's immune system to avoid attacking the tumor. Radiation therapy prevents glioblastoma from growing. Giving WP1066 with radiation therapy may prevent glioblastoma from growing and prolong survival.
Primary Outcome
For PFS analysis, disease progression is defined as progressive disease (PD) per Response Assessment in Neuro-Oncology (RANO) criteria Will be summarized using the Kaplan-Meier method.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Magnetic Resonance Imaging
- RADIATION Radiation Therapy
- PROCEDURE Surgical Procedure
- DRUG STAT3 Inhibitor WP1066
Study Locations (2)
Illinois
- Northwestern University - Chicago
- Northwestern Medicine: Warrenville - Warrenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2024-05-22 |
| Est. Completion | 2028-12-27 |
| Phase | Phase 2 |
What NCT05879250 shows while recruiting
NCT05879250 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 275-participant average among 15 other Glioblastoma, IDH-wildtype trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Glioblastoma, IDH-wildtype appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT05879250 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05879250 about?
NCT05879250 is a clinical study titled "WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma". This phase II trial tests how well the combination of WP1066 and radiation therapy works in treating newly diagnosed glioblastoma. Glioblastoma is difficult to treat effectively because the cells within the tumor vary widely and are controlled by factors within and around the tumor, requiring multip...
What is the current status of trial NCT05879250?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2024-05-22. Estimated completion is 2028-12-27.
What conditions does trial NCT05879250 study?
This clinical trial studies the following conditions: Glioblastoma, IDH-wildtype, MGMT-Unmethylated Glioblastoma.
What interventions are being tested in trial NCT05879250?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Radiation Therapy (RADIATION), Surgical Procedure (PROCEDURE), STAT3 Inhibitor WP1066 (DRUG).
Who is sponsoring clinical trial NCT05879250?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05879250 being conducted?
This trial has 2 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma, IDH-wildtype
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05879250's enrollment target sits among peer trials
39 14th of 15 higher than 2 of 15 other Glioblastoma, IDH-wildtype trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma, IDH-wildtype trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
RECRUITING · Phase 2
-
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
ACTIVE NOT RECRUITING · Phase 2
-
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
RECRUITING
-
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
RECRUITING
-
A Study of 177Lu-PSMA-617 in People With Gliomas
RECRUITING · Phase 1
-
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI